东亚专家意见:慢性乙型肝炎的治疗启动
东亚10位专家在线会议形成慢性乙型肝炎治疗启动的专家意见,基于丙氨酸氨基转移酶(ALT)、乙型肝炎病毒(HBV)DNA、肝硬化和肝细胞癌(HCC)风险评分推荐抗病毒治疗启动时机,并建议对至少有两项HCC风险因素者启动抗病毒治疗或每3个月密切监测。
要点
- HBV DNA≥2000 IU/mL且ALT≥1倍正常上限(ULN)者推荐抗病毒治疗。
- 肝硬化且HBV DNA可检测者无论ALT水平均应治疗。
- 至少两项HCC风险因素者推荐启动抗病毒治疗或每3个月密切监测。
核心结论
- 这些专家推荐将有助于推动东亚地区日常临床实践的新标准。
研究设计与样本
- 东亚10位专家在线会议,讨论ALT、HBV DNA、肝硬化和HCC风险评分,并回顾最新国际指南中CHB治疗指征,汇总共识形成治疗启动推荐。
主要发现
- 推荐对HBV DNA≥2000 IU/mL且ALT≥1×ULN的CHB患者进行抗病毒治疗。
- 推荐对HBV DNA≥2000 IU/mL、ALT<1×ULN且≥F2纤维化和/或≥A2坏死性炎症的CHB患者进行抗病毒治疗。
- 推荐对肝硬化且HBV DNA可检测的CHB患者进行抗病毒治疗。
- 推荐对HBV DNA≥2000 IU/mL、ALT<1×ULN且有肝硬化或HCC家族史、肝外表现或年龄>40岁的CHB患者进行抗病毒治疗。
- 肝硬化和/或HCC患者若HBV DNA可检测,无论ALT水平均应治疗。
关键数值与推荐
- 抗病毒治疗推荐:HBV DNA≥2000 IU/mL且ALT≥1×ULN。
- 抗病毒治疗推荐:HBV DNA≥2000 IU/mL、ALT<1×ULN且≥F2纤维化和/或≥A2坏死性炎症。
- 抗病毒治疗推荐:肝硬化且HBV DNA可检测。
- 抗病毒治疗推荐:HBV DNA≥2000 IU/mL、ALT<1×ULN且有肝硬化或HCC家族史、肝外表现或年龄>40岁。
- 至少两项HCC风险因素的CHB患者推荐启动抗病毒治疗或每3个月密切监测。
临床怎么用
- 根据ALT水平、HBV DNA水平、肝硬化和HCC风险评分启动CHB抗病毒治疗。
- 肝硬化和/或HCC患者HBV DNA可检测时无论ALT水平均应治疗。
- 至少两项HCC风险因素者可启动抗病毒治疗或每3个月密切监测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Globally, chronic hepatitis B (CHB) is a major public health concern. Timely and effective management can prevent disease progression to cirrhosis and reduce the risk of hepatocellular carcinoma (HCC). Currently, there is no consensus on the clinical management of CHB in East Asia. AIM: To establish an East Asia expert opinion on treatment initiation for CHB based on alanine aminotransferase (ALT) level, hepatitis B virus (HBV) deoxyribonucleic acid (DNA) level, cirrhosis and HCC risk scores. METHODS: A meeting was held online with a panel of 10 experts from East Asia to discuss ALT, HBV DNA, cirrhosis and HCC risk scores. Indications for CHB treatment in the latest international guidelines were reviewed. Consensus was summarised to provide recommendations on the initiation of treatment for CHB. RESULTS: Anti-viral therapy is recommended for CHB patients with (a) HBV DNA ≥ 2000 IU/mL and ALT ≥ 1× upper limit of normal (ULN); (b) HBV DNA ≥ 2000 IU/mL, ALT < 1× ULN and ≥ F2 fibrosis and/or ≥ A2 necroinflammation occurs; (c) cirrhosis and detectable HBV DNA; or (d) HBV DNA ≥ 2000 IU/mL, ALT < 1× ULN and a family history of cirrhosis or HCC, extrahepatic manifestations or age > 40 years. Patients with cirrhosis and/or HCC should be treated regardless of ALT levels if HBV DNA level is detectable. Initiating anti-viral therapy or close monitoring at 3-month intervals is recommended for CHB patients with at least two HCC risk factors. CONCLUSIONS: These expert recommendations will contribute to a new standard of daily clinical practice in East Asia.
引用
- Kao JH, Hu TH, Jia J, et al. East Asia expert opinion on treatment initiation for chronic hepatitis B. Aliment Pharmacol Ther. 2020. PMID: 32951256. doi:10.1111/apt.16097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。